Navigation Links
Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
Date:8/18/2009

SAN DIEGO, Aug. 18 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Food and Drug Administration.

AM461 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The submission of the AM461 IND follows closely on the heels of Amira's lead DP2 antagonist, AM211, which is currently in Phase I human testing.

"Taking two DP2 candidates into clinical trials within four months of each other demonstrates our conviction to the target as well as the depth of our DP2 program," said Peppi Prasit, Chief Scientific Officer. "AM461 is structurally and metabolically distinct from AM211."

DP2 is also known as CRTH2, or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for the prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.


'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Touro University California,s College of Pharmacy is pleased ... of a $150,000 grant by the Joseph & Vera ... research and classroom space on its campus. ... of health sciences, and will help us apply high-tech ... our students," said Shelley Berkley , CEO and ...
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are ... professionals, a Systematic Review of Sexual Satisfaction . ... the International Journal of Clinical and Health Psychology. , ... a need to have accurate information about sexual satisfaction ... possible. The material provides a systematic review of ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
(Date:7/31/2014)... Cosmetic Town is a new web ... consumers considering cosmetic treatments. The site features doctors ... is to educate prospective patients on a variety of ... validated referral system that helps patients find cosmetic specialists ... respective fields. , Cosmetic Town started its recruitment ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:The New Doctors’ Directory, Cosmetic Town Does the Research for Consumers of Plastic Surgeries 2
... 60-year-old drug chloroquine eliminated certain malignancies in mice, researchers ... common anti-malaria drug called chloroquine can also prevent the ... a U.S. study finds. , The finding may help ... , Scientists at The Scripps Institute and St. Jude,s ...
... to protect the heart, can lead to halting of ... News) -- Men undergoing hormone therapy for prostate cancer ... a significantly higher risk of dying, new research suggests. ... to elevate liver-function test levels. The end result is ...
... Therapy that stimulates the hand muscles may help treat ... causes muscles spasms in musicians, according to a study ... Neurology, the medical journal of the American Academy of ... practiced particular complicated movements for years. The muscle spasms ...
... Inc. (Nasdaq: GTIV ), the nation,s leading provider ... it is,scheduled to present from 1:30 p.m. to 2:00 ... JPMorgan Healthcare Conference in San Francisco., The event ... audio web cast,which may be accessed by visiting ...
... Medical,Affiliates, Inc. (OTC Bulletin Board: UCIA) reported that revenue ... from $63,672,000 for,the year ended September 30, 2006, an ... September 30, 2007 was $17,885,000 or 9%,greater than the ... increase in revenues is attributed to the opening of ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
Cached Medicine News:Health News:Malaria Drug Promising Against Cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Stimulating muscles may improve musician's dystonia 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 2Health News:UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3
... to 10 inches/ 25 cm thinner than other benchtop ... X-22 Series is the space-saving multipurpose solution for your ... 46 cm wide • 11 Rotor Library • Achieve ... to Spin 1.5 mL & PCR+ Tubes: 24-place ...
... purpose centrifuges offer high-volume versatility along with ... making them ideal for a wide variety ... Four- or six-place sealed swinging bucket ... rotors offered , Lare capacity (4 x ...
... designed to accommodate over 55 centrifuge tubes, ... heat labile samples. Incorporating the latest technology, ... automatic quick cooling from 22 C to ... maintenance brushless motor, low pitch 62 dBA ...
Inquire...
Medicine Products: